PE20151543A1 - Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso - Google Patents

Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso

Info

Publication number
PE20151543A1
PE20151543A1 PE2015001930A PE2015001930A PE20151543A1 PE 20151543 A1 PE20151543 A1 PE 20151543A1 PE 2015001930 A PE2015001930 A PE 2015001930A PE 2015001930 A PE2015001930 A PE 2015001930A PE 20151543 A1 PE20151543 A1 PE 20151543A1
Authority
PE
Peru
Prior art keywords
oral pharmaceutical
methods
pharmaceutical composition
tablets
sulphate salts
Prior art date
Application number
PE2015001930A
Other languages
English (en)
Spanish (es)
Inventor
Jr Edmund V Dennett
David S Wells
Original Assignee
Braintree Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braintree Lab filed Critical Braintree Lab
Publication of PE20151543A1 publication Critical patent/PE20151543A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D5/00—Sulfates or sulfites of sodium, potassium or alkali metals in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2015001930A 2013-03-15 2014-03-14 Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso PE20151543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361798759P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20151543A1 true PE20151543A1 (es) 2015-11-29

Family

ID=50680164

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001930A PE20151543A1 (es) 2013-03-15 2014-03-14 Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso

Country Status (25)

Country Link
US (2) US9919007B2 (https=)
EP (2) EP2968174B1 (https=)
JP (2) JP6441890B2 (https=)
CN (2) CN105142617B (https=)
AU (3) AU2014227598B2 (https=)
BR (1) BR112015019776A2 (https=)
CA (1) CA2903283C (https=)
CY (1) CY1122387T1 (https=)
DK (1) DK2968174T3 (https=)
EA (2) EA034234B1 (https=)
ES (1) ES2764462T3 (https=)
HK (1) HK1214519A1 (https=)
HR (1) HRP20192227T1 (https=)
HU (1) HUE046754T2 (https=)
IL (1) IL241367A0 (https=)
LT (1) LT2968174T (https=)
ME (1) ME03656B (https=)
MX (1) MX377525B (https=)
PE (1) PE20151543A1 (https=)
PL (1) PL2968174T3 (https=)
PT (1) PT2968174T (https=)
RS (1) RS59667B1 (https=)
SI (1) SI2968174T1 (https=)
SM (1) SMT201900716T1 (https=)
WO (1) WO2014144407A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046754T2 (hu) 2013-03-15 2020-03-30 Braintree Laboratories Inc Kettõs felhasználású orális gyógyszer kompozíció tabletták szulfát sókból és eljárás ezek alkalmazására
EP3191105A4 (en) * 2014-09-12 2018-05-02 Braintree Laboratories, Inc. Sulfate salt solution laxative compositions and methods of use thereof
US11007170B2 (en) 2017-02-02 2021-05-18 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
JP2023549291A (ja) * 2020-10-26 2023-11-22 ブレーンツリー・ラボラトリーズ・インコーポレイテッド 結腸洗浄のための硫酸塩製剤
CN116509809B (zh) * 2023-04-19 2024-12-03 山东齐都药业有限公司 复方硫酸钠片剂及其制备方法与应用
US12239659B2 (en) 2023-06-15 2025-03-04 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873694A (en) 1973-09-27 1975-03-25 Cpc International Inc Direct compression tabletting composition and pharmaceutical tablets produced therefrom
JPS5438167B2 (https=) 1974-04-27 1979-11-19
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2058565B (en) 1979-09-21 1983-12-07 Leo Pharm Prod Ltd Layer tablets
NZ198241A (en) 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3134591A1 (de) 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPS5839618A (ja) 1981-09-04 1983-03-08 Chugai Pharmaceut Co Ltd 持続性積層錠剤
EP0080862B1 (en) 1981-12-02 1985-09-25 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS59101423A (ja) 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
JPS6097919A (ja) 1983-11-01 1985-05-31 Furointo Sangyo Kk 圧縮成形用賦形剤の製造方法
NL8400911A (nl) 1984-03-22 1985-10-16 Dagra Nv Werkwijze ter bereiding van een farmaceutische toedieningsvorm die tetracycline of doxycyclinezouten bevat.
EP0231356A1 (en) 1985-08-01 1987-08-12 Braintree Laboratories, Inc. Low-sodium laxative and lavage formulation
US4753801A (en) 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
EP0281200B1 (en) 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
NO168563C (no) 1987-09-28 1992-03-11 Collett Marwell Hauge As Anvendelse av en organoleptisk akseptabel blanding av magnesiumsalter som mineraladditiv
JPH0194937A (ja) * 1987-10-06 1989-04-13 Yokohama Yushi Kogyo Kk 微粉状ミネラル類の被覆物の製造方法
US4837030A (en) 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5274001A (en) 1987-12-24 1993-12-28 Borody Thomas J Orthostatic lavage solutions
WO1989009604A1 (en) 1988-04-05 1989-10-19 Dale Driver Dietary mineral sulfur supplement
JPH0816061B2 (ja) 1988-07-13 1996-02-21 森下ルセル株式会社 腸管洗浄液用組成物と腸管洗浄液
IT1229568B (it) 1989-04-17 1991-09-04 Giuliani Spa Composizione farmaceutica per uso orale adatta all'impiego nel lavaggio gastro intestinale, in particolare per uso diagnostico, oppure come lassativo catartico.
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
DK0630192T3 (da) 1992-03-11 1996-12-09 Procter & Gamble Psyllium-drikkeblandingsprodukter indeholdende granuleret base
EP0670725A1 (en) 1992-11-24 1995-09-13 Block Drug Company, Inc. Pharmaceutical compositions for use in gastrointestinal washes
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5498425A (en) 1995-03-17 1996-03-12 Block Drug Company, Inc. Phosphosoda buffered saline laxative
US5710183A (en) 1995-07-14 1998-01-20 Halow; George M. Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
DK0858326T3 (da) 1996-05-08 2003-07-07 Craig A Aronchick Ikke-vandige colonafføringsmidler
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
CA2286076C (en) 1997-04-18 2006-12-12 Janssen Pharmaceutica N.V. Use of 5ht3 antagonists for promoting intestinal lavage
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
JP2002528483A (ja) 1998-10-30 2002-09-03 マクニール−ピーピーシー・インコーポレイテッド 顆粒状で自由流動性の薬剤組成物、およびその経口投与のためのストロー状の投与形態
US6645481B1 (en) 2000-09-28 2003-11-11 Braintree Laboratories, Inc. Method of achieving overnight laxation and control of bowel function
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
AUPR590701A0 (en) 2001-06-25 2001-07-19 Colocaps Pty Ltd Laxative preparation
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US6946149B2 (en) 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
US20040071779A1 (en) 2002-10-09 2004-04-15 Keiser Dale Arthur Gelled laxative compositions
US7291324B2 (en) 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
GB0224909D0 (en) 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
US20050152989A1 (en) 2003-07-09 2005-07-14 Braintree Laboratories, Inc. Method for treating irritable bowel syndrome
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
GB0409104D0 (en) 2004-04-23 2004-05-26 Norgine Europe Bv Compressed pharmaceutical compositions
WO2005120501A1 (en) 2004-06-04 2005-12-22 Braintree Laboratories, Inc. Method of bowel cleansing
WO2007013093A2 (en) 2005-04-01 2007-02-01 Shiv Prakash Laxative formulation containing a triphala extract
WO2006118562A1 (en) 2005-04-29 2006-11-09 Inkine Pharmaceutical Company, Inc. Purgative composition and uses thereof
EP1877039A4 (en) 2005-05-06 2010-08-18 Salix Pharmaceuticals Inc Polyethylene glycol GUT CLEANING COMPOSITION
US20070087056A1 (en) 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20070082061A1 (en) 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
JP2009521994A (ja) 2005-12-29 2009-06-11 ブレーントリー ラボラトリーズ インコーポレーティッド 仮想結腸内視鏡検査を目的として結腸を準備するための、浸透圧性緩下薬および刺激性緩下薬を含むキット
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
WO2008141368A1 (en) 2007-05-17 2008-11-27 David Lubowski Combination laxative compositions comprising a colonic stimulant and a bulking laxative
JP2011500711A (ja) 2007-10-17 2011-01-06 トーマス・ジェファーソン・ユニバーシティ 腸の下剤およびその使用
WO2009092039A1 (en) 2008-01-16 2009-07-23 Braintree Laboratories, Inc. Sulfate salt prophylaxis and therapies
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
US20100255122A1 (en) 2009-04-02 2010-10-07 Garren Mary L Edible gelatin bowel preparation and bowel cleansing method
WO2010123901A1 (en) 2009-04-21 2010-10-28 Bachwich Dale R Colon lavage system
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
GB0912487D0 (en) 2009-07-17 2009-08-26 Norgine Bv Improvements in and relating to colon cleansing compositions
GB0913295D0 (en) 2009-07-30 2009-09-02 Norgine Bv Improvements in and relating to pharmaceutical compositions
CA2792647A1 (en) 2010-03-10 2011-09-15 Nogra Pharma Limited Compositions for colon lavage and methods of making and using same
EP2544543A1 (en) 2010-03-12 2013-01-16 Scott Cordray Method of treatment
JP5665372B2 (ja) * 2010-06-02 2015-02-04 旭化成ケミカルズ株式会社 速崩壊性固形製剤
EP2598123A1 (en) * 2010-07-27 2013-06-05 Norgine BV Compositions
KR20130101102A (ko) 2010-11-04 2013-09-12 노어긴 비.브이. 폴리에틸렌글리콜을 포함하는 제제
CN103338768B (zh) 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
CN103282051A (zh) * 2010-12-28 2013-09-04 大鹏药品工业株式会社 口腔内崩解片剂
CN105963701A (zh) 2011-01-28 2016-09-28 布伦特里实验室有限公司 用于肠道清洁的方法、组合物以及包装
CN107260661A (zh) 2011-01-31 2017-10-20 诺金股份有限公司 对组合物的改进和与组合物有关的改进
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
WO2012142572A1 (en) 2011-04-15 2012-10-18 Braintree Laboratories, Inc. Sulfate salts as transit time enhancer
US8778907B2 (en) 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
US20140235730A1 (en) 2011-09-23 2014-08-21 Gavis Pharmaceuticals, Llc Solid, edible, chewable laxative composition
MX352891B (es) 2011-10-27 2017-12-13 Salix Pharmaceuticals Inc Purgantes electroliticos.
US9149493B2 (en) 2011-11-28 2015-10-06 Alfa Wassermann Spa Compositions for bowel cleansing and use thereof
CN104936581A (zh) 2012-08-29 2015-09-23 萨利克斯药品有限公司 用于治疗便秘和相关胃肠道疾病和疾病状态的泻药组合物和方法
MX382868B (es) 2012-09-11 2025-03-13 Norgine Bv Composiciones que comprenden polietilenglicol y ascorbato.
US20140087007A1 (en) 2012-09-27 2014-03-27 Braintree Laboratories, Inc. Bowel cleansing preparations
HUE046754T2 (hu) 2013-03-15 2020-03-30 Braintree Laboratories Inc Kettõs felhasználású orális gyógyszer kompozíció tabletták szulfát sókból és eljárás ezek alkalmazására

Also Published As

Publication number Publication date
EP2968174A1 (en) 2016-01-20
EA201992382A3 (ru) 2020-05-31
ES2764462T3 (es) 2020-06-03
US20160030473A1 (en) 2016-02-04
JP2016514677A (ja) 2016-05-23
ME03656B (me) 2020-07-20
DK2968174T3 (da) 2019-12-16
US20180207200A1 (en) 2018-07-26
CA2903283C (en) 2023-09-05
IL241367A0 (en) 2015-11-30
MX377525B (es) 2025-03-10
AU2019201511A1 (en) 2019-03-28
EA201992382A2 (ru) 2020-02-28
EA201591568A1 (ru) 2015-12-30
MX2015012109A (es) 2016-04-15
SI2968174T1 (sl) 2020-02-28
BR112015019776A2 (pt) 2017-07-18
EP3563838A1 (en) 2019-11-06
CN105142617A (zh) 2015-12-09
PT2968174T (pt) 2020-01-15
AU2014227598B2 (en) 2018-12-06
WO2014144407A8 (en) 2014-11-20
EP2968174B1 (en) 2019-10-16
JP2019023244A (ja) 2019-02-14
JP6724114B2 (ja) 2020-07-15
JP6441890B2 (ja) 2018-12-19
CY1122387T1 (el) 2020-11-25
PL2968174T3 (pl) 2020-05-18
LT2968174T (lt) 2020-01-10
US9919007B2 (en) 2018-03-20
SMT201900716T1 (it) 2020-01-14
EA034234B1 (ru) 2020-01-20
HRP20192227T1 (hr) 2020-02-21
AU2020213378A1 (en) 2020-08-27
CN105142617B (zh) 2018-08-03
WO2014144407A1 (en) 2014-09-18
HUE046754T2 (hu) 2020-03-30
HK1214519A1 (zh) 2016-07-29
CN108904462A (zh) 2018-11-30
CA2903283A1 (en) 2014-09-18
AU2014227598A1 (en) 2015-08-27
RS59667B1 (sr) 2020-01-31

Similar Documents

Publication Publication Date Title
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
HUE046671T2 (hu) Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
EA201590732A1 (ru) Диспергируемая таблетка
BR112016014493A2 (pt) Composição para cuidado oral compreendendo um copolímero de fosfato/acrilato e uso de copolímero de fosfato/acrilato na preparação da composição
ES2475942B1 (es) Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
MX2015011099A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.